Compare AXR & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | PLYX |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 114.1M |
| IPO Year | 2010 | N/A |
| Metric | AXR | PLYX |
|---|---|---|
| Price | $28.78 | $5.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 7.6K | ★ 3.9M |
| Earning Date | 06-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.60 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $12,831,000.00 | N/A |
| Revenue This Year | $12.43 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.60 | $2.20 |
| 52 Week High | $29.00 | $8.15 |
| Indicator | AXR | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 69.19 | 53.24 |
| Support Level | $20.58 | $2.44 |
| Resistance Level | N/A | $7.39 |
| Average True Range (ATR) | 1.09 | 1.10 |
| MACD | 0.12 | 0.41 |
| Stochastic Oscillator | 90.80 | 61.33 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.